Momentum is building to reevaluate the safety of pain relievers like Celebrex amid concerns of heart risks similar to Vioxx.
Researchers warn that these drugs may block substances that prevent heart problems.
FDA scrutiny intensifies as Congressman Tom Davis demands answers on drug safety monitoring.
Merck's withdrawal of Vioxx raises questions about FDA oversight.
Dr. David Graham faced resistance within the FDA for his findings on Vioxx.
Concerns about drug safety persist as Merck's Vioxx withdrawal prompts reevaluation of arthritis medications.
Pfizer's Celebrex also under scrutiny for potential risks.
